ZCMDHealthcare · Health Information ServicesZCMD Stock Forecast: Zhongchao, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 1 Aug 2026 — in the weakest quartile.
ZCMD stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Zhongchao, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Value (6): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Zhongchao, Inc. — and when they’d sell — is the membership.
ZCMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ZCMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ZCMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Zhongchao, Inc. (ZCMD) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.6×
- Price / book
- 0.2×
- EV / EBITDA
- 1.7×
Cheaper than 79% of US stocks
Cheaper than 89% of US stocks
Cheaper than 57% of US stocks
- Revenue growth (YoY)
- −23.2%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −92.0%
- Net margin
- −55.5%
Higher than 10% of US stocks
Higher than 14% of US stocks
Higher than 9% of US stocks
- Return on equity
- −24.9%
- Return on assets
- −15.5%
- Dividend yield
- —
Higher than 29% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ZCMD vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZCMD appears on the weeks it earns a place.
Frequently asked questions about ZCMD stock
How does Ticker Nerd's model rank ZCMD?
As at 1 Aug 2026, Zhongchao, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
What is the ZCMD stock forecast for 2030?
No analyst covering Zhongchao, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZCMD are extrapolating price history, which says nothing about the business.
How has ZCMD stock performed over the past year?
Zhongchao, Inc. returned -99.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Zhongchao, Inc. do?
Zhongchao Inc. is an offshore holding company that operates as a platform-based internet technology and healthcare services provider.
About Zhongchao, Inc.
Zhongchao Inc. is an offshore holding company that operates as a platform-based internet technology and healthcare services provider. Through its subsidiaries and PRC operating entities, the company delivers healthcare information, education, and professional training services primarily in the People’s Republic of China. Zhongchao Inc. focuses on oncology and other major diseases, supporting both healthcare professionals and patients via its MDMOOC-branded online platform, mobile app, WeChat subscription accounts, and website. The company’s offerings include clinical practice training, open classes on medical topics, interactive case studies, continuing education courses, academic conferences and workshops, as well as articles and short educational videos. In addition, Zhongchao Inc. provides patient management, internet healthcare, and pharmaceutical-related services, including sales of patented drugs and specialized programs for tumor and rare diseases. It primarily serves pharmaceutical enterprises, medical institutions, non-profit organizations, and healthcare professionals. Founded in 2012 and headquartered in Shanghai, China, Zhongchao Inc. occupies a niche in the health information services segment of the broader healthcare sector.
CEO Mr. Weiguang Yang · 33 employees · China · https://www.izcmd.com